Natera

Veracyte

Bio-Techne

Agilent Technologies

Beam Therapeutics

Arrowhead Pharmaceuticals

Illumina

BioMarin Pharmaceutical

Sarepta Therapeutics

CRISPR Therapeutics

Global X Genomics & Biotechnology ETF

GNOM tracks an index of global biotech equities, selected and weighted by market cap.

ARK Genomic Revolution Multi-Sector ETF

Goldman Sachs ETF Trust - Goldman Sachs Motif Human Evolution ETF

Disruptive technology is always an interesting play for investors to consider and the genomics market is one to watch closely. According to the “Genomics Market – Growth, Trends, and Forecasts (2020-2025),” exponential growth in the space will occur within the next five years.

The Genomics Market is Poised for Growth Through 2025

Global X Robotics & Artificial Intelligence ETF

Global X SuperDividend US ETF

Global X Funds - Global X E-commerce ETF

Global X Video Games & Esports ETF 

Global X Longevity Thematic ETF

Global X Superdividend ETF

The COVID-19 pandemic has created a massive divergence in performance among thematic ETFs.

An ETF For Every Theme: COVID-19 Lightning Round With Global X (Podcast Transcript)

Global X Cloud Computing ETF

Invesco S&P 500 Equal Weight Technology ETF

Vanguard Information Technology ETF

Technology Select Sector SPDR Fund

Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.

Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says

Global X Lithium & Battery Tech ETF

Global X NASDAQ 100 Covered Call ETF

VanEck Vectors Semiconductor ETF

An ETF For Every Theme: COVID-19 Lightning Round With Global X (Podcast)

SPDR S&P Biotech ETF

Biotechnology sector-related exchange traded funds were among the leaders on Monday after Invitae Corp. (NYSE: NVTA) announced a $1.4 billion deal for ArcherDX, potentially bolstering the genetic information company’s offering lineup and growth outlook.

Biotech ETFs Surge After Invitae Acquires ArcherDX

In the scramble to develop a Coronavirus vaccine, genomics investments are receiving renewed attention and rewarding investors in the process. Those sentiments are applicable to the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM), which is higher by more than 52% in the current quarter.

A Genomics ETF at the Center of the Coronavirus Fight

iShares U.S. Oil Equipment & Services ETF

Invesco KBW High Dividend Yield Financial ETF

Amplify Junior Silver Miners ETF

Let us dig into some of the ETFs that are below $20 and are from the hottest areas currently. These low-priced ETFs could lead to huge gains in the coming months.

ETFs Under $20 From 5 Hottest Zones

The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are delivering impressive returns.

3 Genomics ETFs Worth Jumping For

The ETF GNOM hit a 52-week high on May 22. Can it rally further?

Genomics ETF (GNOM) Hits New 52-Week High

iShares Genomics Immunology and Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.

Profit from the Genomics Market Momentum With These ETFs

Declining costs are viewed as one of the biggest factors driving the genomics and data suggest those costs continue falling, a scenario that could benefit ETFs, such as the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM). GNOM tracks the Solactive Genomics Index and “seeks to invest in companies that potentially stand to benefit from [.

Declining Costs Boost Allure of GNOM Genomics ETF

Due in large part to the J.P. Morgan Health Care conference in San Francisco, the biotechnology industry’s marquee yearly confab, January is often a strong month for related equities and ETFs.

Why This Thematic Healthcare Could be a January Winner

Virtus LifeSci Biotech Clinical Trials ETF

Invesco Dynamic Oil & Gas Services ETF

ALPS Medical Breakthroughs ETF

Global X Silver Miners ETF

iShares PHLX Semiconductor ETF

SPDR S&P Pharmaceuticals ETF

SPDR S&P Semiconductor ETF

While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.

4 Sector ETFs That Beat the Market in Q4

Global X U.S. Infrastructure Development ETF

We believe cannabis, infrastructure, genomics and longevity are a few themes that could not only withstand a potential recession, but also perhaps thrive.

Themes For Defensive Positioning

Loncar Cancer Immunotherapy ETF

iShares Nasdaq Biotechnology ETF

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Biotech ETFs Hit New Highs on Deal Activities

MeiraGTx Holdings plc

Intellia Therapeutics

Pieris Pharma

uniQure

Vertex Pharmaceuticals

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Gene Therapy the Next Best Thing: Here's Why (Revised)

The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.

Genomics ETFs Surge on CRISPR's Gene Editing Progress

iShares U.S. Healthcare Providers ETF

Ironwood Pharma

Jounce Therapeutics

Osmotica Pharmaceuticals Plc

Select Medical Holdings

Healthcare bounced back with an outperformance starting the fourth quarter.

Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

Healthcare ETFs Win in October: Here's Why

When it comes to growth stocks, investors often expect they will pay up to access that.

This High Growth ETF May Not Be As Pricey As You Think

The Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted earlier this year, making it one of the newest additions to the biotech ETFs fray, but despite its rookie status, GNOM is a fund with ample potential for risk-tolerant, long-term investors. GNOM tracks the Solactive Genomics Index and “seeks to invest in companies that potentially [.

News for Global X Genomics & Biotechnology ETF ETF (GNOM)